These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 2632270)
1. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270 [No Abstract] [Full Text] [Related]
2. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group. Smyth JF; Gundersen S; Renard J; Pinedo HM Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350 [No Abstract] [Full Text] [Related]
3. A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung. Vibe-Petersen J; Bach F; Pedersen AG; Smyth J; Hansen HH Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1881-5. PubMed ID: 2561100 [No Abstract] [Full Text] [Related]
4. Phase I study of TCNU, a novel nitrosourea. Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348 [TBL] [Abstract][Full Text] [Related]
5. Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. van Oosterom AT; Stoter G; Bono AV; Splinter TA; Fossa SD; Verbaeys AJ; de Mulder PH; de Pauw M; Sylvester R Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1249-50. PubMed ID: 2767112 [No Abstract] [Full Text] [Related]
6. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group. Gundersen S; Dombernowsky P; Cavalli F; Bruntsch U; Renard J; Van Glabbeke M; Pinedo H Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1095-7. PubMed ID: 2759163 [TBL] [Abstract][Full Text] [Related]
7. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU). Vibe-Petersen J; Bork E; Møller H; Hansen HH Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of TCNU in advanced breast cancer. Dombernowsky P; Clavel M; Smyth JF; Howell A; van Glabekke M; Renard J; Pinedo HM Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1377-8. PubMed ID: 3181260 [No Abstract] [Full Text] [Related]
9. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Smyth JF; Hardcastle JD; Denton G; Alderson D; Grace RH; Mansi JL; Yosef HM; Nordle O; Lauri H; Wählby S Ann Oncol; 1995 Nov; 6(9):948-9. PubMed ID: 8624301 [No Abstract] [Full Text] [Related]
10. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. van Oosterom AT; Fosså SD; Pizzocaro G; Bergerat JP; Bono AV; De Pauw M; Sylvester R Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1239-41. PubMed ID: 6541582 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of tauromustine in disseminated malignant melanoma. Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342 [TBL] [Abstract][Full Text] [Related]
12. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Elson PJ; Earhart RH; Kvols LK; Spiegel R; Keller AM; Kies MS; Davis TE; Stevens C; Gumas L; Trump DL Cancer Treat Rep; 1987 Mar; 71(3):331-2. PubMed ID: 3815401 [No Abstract] [Full Text] [Related]
13. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society. Gatzemeier U; Drings P; Edler L; Fiebig HH; Hinke A; Rieche K; Tessen HW Onkologie; 1990 Jun; 13(3):186-8. PubMed ID: 2168534 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of cystemustine in advanced renal cancer. Chauvergne J; Kerbrat P; Adenis A; Chollet P; Fargeot P; Pujade-Lauraine E; Dieras V; Madelmont JC; Lentz MA; Toulouse C Eur J Cancer; 1995; 31A(1):130-1. PubMed ID: 7695969 [No Abstract] [Full Text] [Related]
15. Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study. Ernst P; Balslev I; Mouridsen HT Cancer Treat Rep; 1987 Oct; 71(10):987-8. PubMed ID: 3652062 [No Abstract] [Full Text] [Related]
16. TCNU: a ray of hope for designer nitrosoureas? Workman P Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1823-8. PubMed ID: 3325292 [No Abstract] [Full Text] [Related]
17. TCNU in adenocarcinoma of the lung: a phase II study with divided doses. Sørensen JB; Bach F; Dombernowsky P; Vibe-Petersen J; Hansen HH Ann Oncol; 1990 Jul; 1(4):299-300. PubMed ID: 2265139 [TBL] [Abstract][Full Text] [Related]
18. TCNU in colorectal cancer. How many patients are needed to demonstrate that a drug doesn't work? Wils J Ann Oncol; 1996 Feb; 7(2):211. PubMed ID: 8777181 [No Abstract] [Full Text] [Related]
19. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours. Bibby MC; Double JA; Morris CM Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Lasset C; Merrouche Y; Negrier S; Rebattu P; Berille J; Bizzari JP; Chauvin F; Philip T Cancer Chemother Pharmacol; 1993; 32(4):329-31. PubMed ID: 8324878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]